The environment and Parkinson's disease: Is the nigrostriatal system preferentially targeted by neurotoxins?

Lancet Neurology

Volumn 2, Issue 9, 2003, Pages 531-538

  Di Monte, Donato A ^a  

^a PARKINSON S INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METAL; NEUROTOXIN; PESTICIDE;

CELL DAMAGE; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; GENE INTERACTION; HUMAN; MEDICAL INFORMATION; MITOCHONDRION; MOLECULAR INTERACTION; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 0042521076     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(03)00501-5     Document Type: Review

References (71)

1. Tanner C.M., Ottman R., Goldman S.M., et al. Parkinson disease in twins: an etiologic study. JAMA. 281:1999;341-346.
2. 18F-dopa and positron emission tomography. Neurology. 42:1992;1894-1900.
3. Holthoff V.A., Vieregge P., Kessler J., et al. Discordant twins with Parkinson's disease: positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol. 36:1994;176-182.
4. Piccini P., Burn D.J., Ceravolo R., Maraganore D., Brooks D.J. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol. 45:1999;577-582.
5. 18F]6-fluorodopa PET. J Neurol. 247:(suppl 2):2000;II110-II113.
6. Auluck P.K., Chan H.Y., Trojanowski J.Q., Lee V.M., Bonini N.M. Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson's disease. Science. 295:2002;865-868.
7. Ross G.W., Abbott R.D., Petrovitch H., et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. 283:2000;2674-2679.
8. Ascherio A., Zhang S.M., Hernan M.A., et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol. 50:2001;56-63.
9. Sugita M., Izuno T., Tatemichi M., Otahara Y. Meta-analysis for epidemiologic studies on the relationship between smoking and Parkinson's disease. J Epidemiol. 11:2001;87-94.
10. Morens D.M., Grandinetti A., Reed D., White L.R., Ross G.W. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology. 45:1995;1041-1051.
11. Elbaz A., Bower J.H., Peterson B.J., et al. Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol. 60:2003;91-96.
12. Gorell J.M., Rybicki B.A., Johnson C.C., Peterson E.L. Smoking and Parkinson's disease: a dose-response relationship. Neurology. 52:1999;115-119.
13. Tanner C.M., Goldman S.M., Aston D.A., et al. Smoking and Parkinson's disease in twins. Neurology. 58:2002;581-588.
14. Quik M., Kulak J.M. Nicotine and nicotinic receptors; relevance to Parkinson's disease. Neurotoxicology. 23:2002;581-594.
15. Allam M.F., Serrano del Castillo A., Fernandez-Crehuet Navajas R. Smoking and Parkinson's disease: explanatory hypothesis. Int J Neurosci. 112:2002;851-854.
16. Fowler J.S., Volkow N.D., Wang G.J., et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature. 379:1996;733-736.
17. Earle K.M. Studies on Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed brain tissue. J Neuropathol Exp Neurol. 27:1968;1-14.
18. Dexter D.T., Wells F.R., Lees A.J., et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. JNeurochem. 52:1989;1830-1836.
19. Uversky V.N., Li J., Fink A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human α-synuclein. J Biol Chem. 276:2001;44284-44296.
20. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA. 95:1998;6469-6473.
21. Gorell J.M., Johnson C.C., Rybicki B.A., et al. Occupational exposure to metals as risk factors for Parkinson's disease. Neurology. 48:1997;650-658.
22. Seidler A., Hellenbrand W., Robra B.P., et al. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology. 46:1996;1275-1284.
23. Semchuk K.M., Love E.J., Lee R.G. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology. 42:1992;1328-1335.
24. Liou H.H., Tsai M.C., Chen C.J., et al. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology. 48:1997;1583-1588.
25. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., Richardson R.J. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology. 50:1998;1346-1350.
26. Petrovitch H., Ross G.W., Abbott R.D., et al. Plantation work and risk of Parkinson's disease in a population-based longitudinal study. Arch Neurol. 59:2002;1787-1792.
27. Uversky V.N., Li J., Fink A.L. Pesticides directly accelerate the rate of α-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett. 500:2001;105-108.
28. Uversky V.N., Li J., Bower K., Fink A.L. Synergistic effects of pesticide and metals on the fibrillation of α-synuclein: implications for Parkinson's disease. Neurotoxicology. 23:2002;527-536.
29. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
30. Di Monte D.A., Lavasani M., Manning-Bog A.B. Environmental factors in Parkinson's disease. Neurotoxicology. 23:2002;487-502.
31. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., Karluk D. Evidence of active nerve degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol. 46:1999;598-605.
32. Forno L.S., Langston J.W., DeLanney L.E., Irwin I., Ricaurte G.A. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol. 20:1986;449-455.
33. Di Monte D.A., Royland J.E., Irwin I., Langston J.W. Astrocytes as the site for bioactivation of neurotoxins. Neurotoxicology. 17:1996;697-703.
34. Javitch J.A., D'Amato R.J., Strittmatter S.M., Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA. 82:1985;2173-2177.
35. Daniels A.J., Reinhard J.F. Jr. Energy-driven uptake of the neurotoxin 1-methyl-4-phenylpyridinium into chromaffin granules via the catecholamine transporter. J Biol Chem. 263:1988;5034-5036.
36. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36:1985;2503-2508.
37. Ramsay R.R., Singer T.P. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J Biol Chem. 261:1986;7585-7587.
38. Schapira A.H., Mann V.M., Cooper J.M., et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem. 55:1990;2142-2145.
39. Miller G.W., Kirby M.L., Levey A.I., Bloomquist J.R. Heptachlor alters expression and function of dopamine transporters. Neurotoxicology. 20:1999;631-637.
40. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuma M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci. 3:2000;1301-1306.
41. Sherer T.B., Kim J.H., Betarbet R., Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and α-synuclein aggregation. Exp Neurol. 179:2003;9-16.
42. Sherer T.B., Betarbet R., Stout A.K., et al. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered α-synuclein metabolism and oxidative damage. J Neurosci. 22:2002;7006-7015.
43. Cleeter M.W., Cooper J.M., Schapira A.H. Irreversible inhibition of mitochondrial complex by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J Neurochem. 58:1992;786-789.
44. McLennan H.R., Degli Esposti M. The contribution of mitochondrial respiratory complexes to the production of reactive oxygen species. J Bioenerg Biomembr. 32:2000;153-162.
45. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol. 14:1978;633-643.
46. Fitsanakis V.A., Amarnath V., Moore J.T., Montine K.S., Zhang J., Montine T.J. Catalysis of catechol oxidation by metal-dithiocarbamate complexes in pesticides. Free Radic Biol Med. 33:2002;1714-1723.
47. Degli Esposti M. Inhibitors of NADH-ubiquinone reductase: an overview. Biochim Biophys Acta. 1364:1998;222-235.
48. McCormack A.L., Thiruchelvam M., Manning-Bog A.B., et al. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis. 10:2002;119-127.
49. Manning-Bog A.B., McCormack A.L., Li J., Uversky V.N., Fink A.L., Di Monte D.A. The herbicide paraquat causes up-regulation and aggregation of α-synuclein in mice. J Biol Chem. 277:2002;1641-1644.
50. Shimizu K., Ohtaki K., Matsubara K., et al. Carrier-mediated processes in blood-brain barrier penetration and neural uptake of paraquat. Brain Res. 906:2001;135-142.
51. McCormack A.L., Di Monte D.A. Effects of l-dopa and other amino acids against paraquat-induced nigrostriatal degeneration. J Neurochem. 85:2003;82-86.
52. Corsini G.U., Pintus S., Chiueh C.C., Weiss J.F., Kopin I.J. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate. Eur J Pharmacol. 119:1985;127-128.
53. Walters T.L., Irwin I., Delfani K., Langston J.W., Janson A.M. Diethyldithiocarbamate causes nigral cell loss and dopamine depletion with nontoxic doses of MPTP. Exp Neurol. 156:1999;62-70.
54. Thiruchelvam M., Richfield E.K., Baggs R.B., Tank A.W., Cory-Slechta D.A. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J Neurosci. 20:2000;9207-9214.
55. Manning-Bog AB, McCormack AL, Lavasani M, DiMonte DA. Parkinson's disease-like pathology in a mouse model of metal-pesticide co-exposure. Proceedings of the Society for Neuroscience (Orlando), 2002: 595.17.
56. Gao H.M., Hong J.S., Zhang W., Liu B. Synergistic dopaminergic neurotoxicity of the pesticide rotenone and the inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. J Neurosci. 23:2003;1228-1236.
57. Koller W.C. When does Parkinson's disease begin? Neurology. 42:(suppl 4):1992;27-31.
58. Ling Z., Gayle D.A., Ma S.Y., et al. In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Mov Disord. 17:2002;116-124.
59. Liberatore G.T., Jackson-Lewis V., Vukosavic S., et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med. 5:1999;1403-1409.
60. Bolin L.M., Strycharska-Orczyk I., Murray R., Langston J.W., Di Monte D.A. Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice. J Neurochem. 83:2002;167-175.
61. Polymeropoulos M.H., Lavedan C., Leroy E., et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047.
62. Kruger R., Kuhn W., Muller T., et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet. 18:1998;106-108.
63. Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowerc M., Przedborski S. α-Synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem. 74:2000;721-729.
64. Masliah E., Rockenstein E., Veinbergs I., et al. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science. 287:2000;1265-1269.
65. Matsuoka Y., Vila M., Lincoln S., et al. Lack of nigral pathology in transgenic mice expressing human α-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol Dis. 8:2001;535-539.
66. Manning-Bog A.B., McCormack A.L., Purisai M.G., Bolin L.M., Di Monte D.A. α-Synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci. 23:2003;3095-3099.
67. Clayton D.F., George J.M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 21:1998;249-254.
68. Giasson B.I., Duda J.E., Murray I.V., et al. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science. 290:2000;985-989.
69. Bonifati V., Rizzu P., van Baren M.J., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 299:2003;256-259.
70. Mitsumoto A., Nakagawa Y. DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin. Free Radic Res. 35:2001;885-893.
71. Mitsumoto A., Nakagawa Y., Takeuchi A., Okawa K., Iwamatsu A., Takanezawa Y. Oxidized forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal levels of paraquat. Free Radic Res. 35:2001;301-310.